| Literature DB >> 34514757 |
Xin Wen1, Hui Qiu1, Zhiying Shao2, Guihong Liu1, Nianli Liu3, Aoxing Chen1, Xingying Zhang1, Xin Ding4, Longzhen Zhang5,6,7.
Abstract
Until now, there has been a lack of standard and effective treatments for patients with recurrent malignant tumors or abdominal and pelvic malignancies with extensive invasion (Morris, 2000). Generally, these patients face problems such as inability to undergo surgery or chemotherapy resistance (Combs et al., 2016). Re-radiotherapy has achieved a prominent place in the treatment of patients who have received radiotherapy previously and developed in-field recurrences (Straube et al., 2018). However, re-radiotherapy is very complicated, requiring comprehensive consideration of appropriate radiation dose, interval from first radiotherapy, boundary of the radiotherapy target area, and damage to surrounding normal tissues (Straube et al., 2019). In other words, it is necessary to focus on the protection of surrounding normal tissues while maximizing the efficacy of re-radiotherapy in such patients.Entities:
Keywords: Abdominal and pelvic cancers; HRS/IRR; PLDR; T1/2
Mesh:
Year: 2021 PMID: 34514757 PMCID: PMC8435343 DOI: 10.1631/jzus.B2000793
Source DB: PubMed Journal: J Zhejiang Univ Sci B ISSN: 1673-1581 Impact factor: 3.066